Antitumor properties of boswellic acid against ehrlich ascites cells bearing mouse

Food and Chemical Toxicology

Volumn 49, Issue 9, 2011, Pages 1924-1934

  Agrawal, S S ^a   Saraswati, Sarita ^a   Mathur, Rajani ^a   Pandey, Maneesha ^a  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

Author keywords

Angiogenesis; Boswellic acid; Caspase 3; Ehrlich ascites tumor; VEGF

Indexed keywords

BOSWELLIC ACID; CASPASE; CYCLOPHOSPHAMIDE; INTERLEUKIN 12; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MOUSE; NONHUMAN; SURVIVAL TIME; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; CARCINOMA, EHRLICH TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; TRITERPENES;

BOSWELLIA SERRATA; BURSERACEAE; MUS;

EID: 79960833790     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2011.04.007     Document Type: Article

References (69)

1. Ammon H.P., Safayhi H., Mack T., Sabieraj J. Mechanism of anti-inflammatory actions of curcumine and boswellic acids. J. Ethnopharmacol. 1993, 38:113-119.
2. Cerutti P.A. Oxy-radicals and cancer. Lancet 1994, 344:862-863.
3. Choudhury S.M., Roy G., Gupta M., Majumder U.K. The central nervous system depressant activities of Mycotoxin MT81 and its acetylated and benzoylated analogues. Al Ameen J. Med. Sci. 2008, 1:104-114.
4. Clarkson B.D., Burchenal J.H. Preliminary screening of antineoplastic drugs. Prog. Clin. Cancer 1965, 1:625-629.
5. Fecchio D., Sirois P., Russo M., Jancar S. Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. Inflammation 1990, 14:125-131.
6. Fenninger L.D., Mider G.B. Advances in cancer research 1954, Academic Press, New York. A. Haddow, J.P. Greenstein (Eds.).
7. Ferrara N. vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
8. Fodstad O., Olsnes S., Alexander Pihl A. Inhibitory effect of abrin and ricin on the growth of transplantable murine tumors and of abrin on human cancers in nude mice. Cancer Res. 1977, 37:4559-4567.
9. Folkman J. Angiogenesis: an organizing principle for drug discovery. Nat. Rev. Drug Discov. 2007, 6:273-286.
10. Gerhardt H., Seifert F., Buvari P., Vogelsang H., Repges R.Z. Therapie desaktiven Morbus Crohn mit Boswellia serrata extract H 15 Z. Gastroenterology 2001, 39:11-17.
11. Glaser T., Winter S., Groscurth P., Safayhi H., Sailer E.R., Ammon H.P., Schabet M., Weller M. Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer 1999, 80:756-765.
12. GLOBOCAN 2008 online accessed on Dec 23'2010. http://globocan.iarc.fr.
13. Gupta M., Chatterjee T. Ind. J. Pharmacol. 1985, 17:195.
14. Gupta I., Parihar A., Malhotra P., Singh G.B., Ludtke R., Safayhi H., Ammon H.P. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur. J. Med. Res. 1997, 2:37-43.
15. Gupta I., Gupta V., Parihar A., Gupta S., Ludtke R., Safayhi H., Ammon H.P. Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a doubleblind, placebo-controlled, 6-week clinical study. Eur. J. Med. Res. 1998, 3:511-514.
16. Gupta I., Parihar A., Malhotra P., Gupta S., Ludtke R., Safayhi H., Ammon H.P. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta. Med. 2001, 67:391-395.
17. Gupta M., Mazumder U.K., Kumar R.S., Sivakumar T., Vamsi M.L.M. Antitumor activity and antioxidant status of Caesalpinia bonducella against Ehrlich ascites carcinoma in Swiss albino mice. J. Pharmacol. Sci. 2004, 94:177-184.
18. Han R. Highlight on the studies of anticancer drugs derived from plants in China. Stem Cells 1994, 12:53-63.
19. Hasan J., Byers R., Jayson G.C. Intra-tumoural microvessel density in human solid tumours. Br. J. Cancer 2002, 86:1566-1577.
20. Hlkatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002, 94:883-893.
21. Hoernlein R.F., Orlikowsky T., Zehrer C., Niethammer D., Sailer E.R., Simmet T., Dannecker G.E., Ammon H.P. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I. J. Pharmacol. Exp. Ther. 1999, 288:613-619.
22. Hostanska K., Daum G., Saller R. Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res. 2002, 22:2853-2862.
23. Huang M.T., Badmaev V., Ding Y., Liu Y., Xie J.G., Ho C.T. Anti-tumor and anti-carcinogenic activities of triterpenoid, β-boswellic acid. Biofactors 2000, 13:225-230.
24. Iqbal M., Okada S. Induction of NAD(P)H:quinone Reductase by Probucol: a Possible Mechanism for Protection against Chemical Carcinogenesis and Toxicity. Pharmacol. Toxicol. 2003, 93:259-263.
25. Jing Y., Nakajo S., Xia L., Nakaya K., Fang Q., Waxman S., Han R. Boswellic acid acetate induces differentiation and apoptosis in leukemia cell lines. Leuk. Res. 1999, 23:43-50.
26. Kennedy D.O., Kojima A., Hasuma T., Yano Y., Otani S., Matsui Y.I. Growth inhibitory effect of green tea extract and (-)-epigallocatechin in Ehrlich Ascites tumor cells involves a cellular thiol-dependent activation of mitogenic-activated protein kinases. Chem. Biol. 2001, 134:113-133.
27. Kiela P.R., Midura A.J., Kuscuoglu N., Jolad S.D., Solyom A.M., Besselsen D.G., Timmermann B.N., Ghishan F.K. Effects of Boswellia serrata in mouse models of chemically induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G798-G808.
28. Kim K.J., Li B., Winer J., Armanini M., Gillet N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-842.
29. Kunnumakkara A.B., Nair A.S., Sung B., Pandey M.K., Aggarwal B.B. Boswellic acid blocks STAT3 Signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1. Mol. Cancer Res. 2009, 7:118-128.
30. Liu J.J., Nilsson A., Oredsson S., Badmaev V., Duan R.D. Keto- and acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int. J. Mol. Med. 2002, 10:501-505.
31. Lu M., Xia L., Hua H., Jing Y. Acetyl-keto-B-Boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. 2008, 68:1180-1186.
32. Luo J.C., Yamaguchi S., Shinkai A., Shitara K., Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998, 58:2652-2660.
33. Ma J. TNF-α and IL-12: a balancing act in macrophage functioning. Microbe. Infect. 2001, 3:121-129.
34. Ma X., Chow J.M., Gri G., Carra G., Gerosa F., Wolf S.F., Dzialo R., Trinchieri G. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J. Exp. Med. 1996, 183:147-157.
35. Maseki M., Nishiagaki I., Hagishara M., Tamoda Y., Yagi K. Lipid peroxidation levels and lipid content of serum lipoprotein fractions of pregnant subjects with or without pre-eclampsia. Clin. Chim. Acta. 1981, 41:424-426.
36. Mates J.M., Perez-Gomez C., Nunez de Castro I. Antioxidant enzymes and human disease. Clin. Biochem. 1999, 32:595-603.
37. Meister A. Glutathione metabolism and its selective modification. J. Biochem. 1988, 263:17205-17208.
38. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 1998, 153:1249-1256.
39. Miller K.D., Sweeney C.J., Sledge G.W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001, 19:1195-1206.
40. Nagata S. DNA degradation in development and programmed cell death. Annu. Rev. Immunol. 2005, 23:853-875.
41. Oberling C., Guerin M. The role of viruses in the production of cancer. Adv. Cancer Res. 1954, 2:323-353.
42. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
43. Pang X., Yi T., Yi Z. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 2009, 69:518-525.
44. Park V.S., Lee J.H., Harwalkar J.A., Bondar J., Safayhi H., Golubic M. Acetyl-11-keto-beta-boswellic acid (AKBA) is cytotoxic for meningioma cells and inhibits phosphorylation of the extracellular-signal regulated kinase 1 and 2. Adv. Exp. Med. Biol. 2002, 507:387-393.
45. Price V.E., Greenfield R.E. Anemia in cancer. Advances in cancer research 1950, 199-200. Academic Press, New York. J.P. Greenstein, A. Haddow (Eds.).
46. Qureshi S., Al-Harbi M.M., Ahmed M.M., Raza M., Giangreco A.B., Shah A.H. Evaluation of the genotoxic, cytotoxic and antitumor properties of Commiphora molmol using normal and Ehrlich ascites carcinoma cell bearing Swiss albino mice. Cancer Chemother. Pharmacol. 1993, 33:130-138.
47. Rebecca C., Daniel B., Yu S., Susan C.K., Robert J.C., Jason D.M. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production and proliferation in colorectal cells. Cancer Res. 1998, 58:2323-2327.
48. Sadick H., Naim R., Gossler U., Hormann K., Riedel F. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int. J. Mol. Med. 2005, 15:15-19.
49. Safayhi H., Mack T., Ammon H.P. Protection by boswellic acids against galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 1991, 41:1536-1537.
50. Safayhi H., Mack T., Sabieraj J., Anazodo M.I., Subramanian L.R., Ammon H.P. Boswellic acids: novel, specific nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther. 1992, 261:1143-1146.
51. Safayhi H., Rall B., Sailer E.R., Ammon H.P. Inhibition by boswellic acids of human leukocyte elastase. J. Pharmacol. Exp. Ther. 1997, 281:460-463.
52. Sailer E.R., Subramanian L.R., Rall B., Hoernlein R.F., Ammon H.P., Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br. J. Pharmacol. 1996, 117:615-618.
53. Salimath B.P., Tabassum A., Anupama E.G., Bindumalini, Preeti G.B., Salimath P.V. Molecular mechanism of action of butyric acid in Ehrlich ascites tumor cells. Nutr. Res. 1999, 19:589-600.
54. Shao Y., Ho C.T., Chin C.K., Badmaev V., Ma W., Huang M.T. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. 1998, 64:328-331.
55. Sharma M.L., Bani S., Singh G.B. Anti-arthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int. J. Immunopharmacol. 1989, 11:647-652.
56. Sharma M.L., Kaul A., Khajuria A., Singh S., Singh G.B. Immunomodulatory activity of boswellic acids (pentacyclic triterpene acids) from Boswellia serrata. Phytother. Res. 1996, 10:107-112.
57. Sinclair A.J., Barnett A.H., Lunie J. Free radical and auto-oxidant systems in health and disease. Br. J. Hosp. Med. 1990, 43:334-344.
58. Singh G.B., Atal C.K. Pharmacology of an extract of salai guggal ex Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions 1986, 18:407-412.
59. Singh S.K., Bhusari S., Singh R., Saxena A., Mondhe D., Qazi G.N. Effect of acetyl 11-keto β-boswellic acid on metastatic growth factor responsible for angiogenesis. Vasc. Pharmacol. 2007, 46:333-337.
60. Sugiura K. Effect of various compounds on the Ehrlich ascites carcinoma. Cancer Res. 1953, 13:431-441.
61. Sur P., Ganguly D.K. Tea plant roots extract (TRE) as an antineoplastic agent. Planta Med. 1994, 60:106-109.
62. Syrovets T., Buchele B., Krauss C., Laumonnier Y., Simmet T. Acetylboswellic acids inhibit lipopolysaccharide-mediated TNF-alpha induction in monocytes by direct interaction with IkappaB kinase. J. Immunol. 2005, 174:498-506.
63. Vainio H., Bianchini F. IARC Working Group on the Evaluation of Cancer-Preventive Strategies IARC Handbooks of Cancer Prevention: Fruit and Vegetables 2001, IARC Press, Lyon.
64. Winking M., Sarikaya S., Rahmanian A., Jodicke A., Boker D.K. Boswellic acids inhibit glioma growth: a new treatment option?. J. Neurooncol. 2000, 46:97-103.
65. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., Tsujinoue H., Fukui H. The angiotensin-I-convertingenzyme inhibitor perindopril suppresses tumor growth and angiogen esis: possible role of the vascular endothelial growth factor. Clin. Cancer Res. 2001, 7:1073-1078.
66. Yoshiji H., Kuriyama S., Ways D.K., Yoshii J., Miyamoto Y., Kawata M., Ikenaka Y., Tsujinoue H., Nakatani T., Shibuya M., Fukui H. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 1999, 59:4413-4418.
67. Zakharova M., Ziegler H.K. Paradoxical anti-inflammatory actions of TNF-α inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J. Immunol. 2005, 175:5024-5033.
68. Zhao W., Entschladen F., Liu H., Niggemann B., Fang Q., Zaenker K.S., Han R. Boswellic acid acetate induces differentiation and apoptosis in highly metastatic melanoma and fibrosarcoma cells. Cancer Detec. Prev. 2003, 27:67-75.
69. Zitvogel L., Couderc B., Mayordomo J.I., Robbins P.D., Lotze M.T., StorkusW J. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann. NY Acad. Sci. 1996, 795:284-293.